专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08748436B2 Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring 有权
标题翻译：具有2,5,7-取代的恶唑啉嘧啶环的羧酸衍生物
公开(公告)号：US08748436B2
公开(公告)日：2014-06-10
申请号：US13521827
申请日：2011-01-12
申请人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Andreas Gille , Katrin Hiss
发明人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Andreas Gille , Katrin Hiss
IPC分类号： A61K31/519
CPC分类号： C07D498/04
摘要： The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2, R3, R4 and X are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing.
摘要翻译：本发明涉及式（I）的恶唑并嘧啶化合物，其中A，R 1，R 2，R 3，R 4和X如权利要求中所定义。式I化合物适用于例如伤口愈合。

12. 发明授权

US08519172B2 Decolorization of polyols 有权
标题翻译：多元醇脱色
公开(公告)号：US08519172B2
公开(公告)日：2013-08-27
申请号：US13513078
申请日：2010-11-15
申请人： David A. Babb , Matthias Schaefer
发明人： David A. Babb , Matthias Schaefer
IPC分类号： C07C51/43
CPC分类号： C08G63/912 , C07C67/03 , C07C67/347 , C07C69/52 , C07C69/675
摘要： Natural oil-based polyols that are high in color, e.g., >40 APHA, are decolorized when exposed to high frequency visible light and/or low frequency UV light, with or without the combination of heat and/or air exposure.
摘要翻译：高达40 APHA的天然油基多元醇，当暴露于高频可见光和/或低频紫外光下时，有或没有加热和/或空气暴露的组合而脱色。

13. 发明申请

US20130072502A1 HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING 有权
标题翻译：具有2,5-取代的氧杂环糊精环的杂环羧酸衍生物
公开(公告)号：US20130072502A1
公开(公告)日：2013-03-21
申请号：US13521828
申请日：2011-01-12
申请人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Katrin Hiss
发明人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Katrin Hiss
IPC分类号： C07D498/04
CPC分类号： C07D498/04
摘要： Heterocyclic carboxylic acid derivatives comprising a 2,5-substituted oxazolopyrimidine ring as Edg-1 receptor agonistsThe present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3, X and Y are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
摘要翻译：包含2,5-取代的恶唑啉嘧啶环作为Edg-1受体激动剂的杂环羧酸衍生物本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1，R 2，R 3，X和Y如声称。式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于例如治疗动脉粥样硬化，心力衰竭或外周动脉闭塞性疾病等疾病。本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。

14. 发明申请

US20110182134A1 MIXING SYSTEM COMPRISING AN EXTENSIONAL FLOW MIXER 审中-公开
标题翻译：包含扩展流量混合器的混合系统
公开(公告)号：US20110182134A1
公开(公告)日：2011-07-28
申请号：US12692009
申请日：2010-01-22
申请人： Maria Pollard , Steven R. Strand , David A. Eversdyk , Matthias Schaefer
发明人： Maria Pollard , Steven R. Strand , David A. Eversdyk , Matthias Schaefer
IPC分类号： B01F5/06
CPC分类号： B01F5/0453 , B01F5/0451 , B01F5/0456
摘要： A mixing system is disclosed comprising at least one extensional flow mixer comprising: a generally open and hollow body having a contoured outer surface and having: a single entrance port and a single exit port; a means for compressing a bulk stream flowing through the generally open and hollow body in a direction of flow and at least one injected additive stream introduced at the single entrance port in the direction of flow; and a means for broadening the bulk stream and the at least one injected additive stream such that an interfacial area between the bulk stream and the at least one injected additive stream is increased as the bulk stream and the at least one injected additive stream flow through the generally open and hollow body in the direction of flow to promote mixing of the bulk stream and the at least one injected additive stream, a flow conductor having an axis and having a generally open and hollow flow mixer body secured therein; and a primary additive stream injector positioned at the entrance port of the generally open and hollow flow mixer body, wherein the primary additive stream injector injects an additive stream into the interior of the flow mixer in the direction of flow when the bulk stream is flowing through the generally open and hollow flow mixer body to allow compression and broadening of the bulk stream and the additive stream together to facilitate mixing of the bulk stream and the primary additive stream at an exit of the extensional flow mixer, wherein the extensional flow mixer is followed by at least one of helical static mixing elements that is at least one half flow conductor diameter downstream of the exit of the extensional flow mixer.
摘要翻译：公开了一种混合系统，该混合系统包括至少一个延伸流动混合器，包括：具有轮廓外表面的大致敞开且中空的主体，具有：单个入口和单个出口; 用于沿流动方向压缩流过大体上敞开的中空体的主体流和沿着流动方向在单个入口处引入的至少一个注入的添加剂流的装置; 以及用于使本体流和至少一个注入的添加剂流扩展的手段，使得当本体流和至少一个注入的添加剂流流过该流体流时，本体流和至少一个注入的添加剂流之间的界面面积增加通常在流动方向上开放和中空的体，以促进本体流和至少一个注入的添加剂流的混合，具有轴线并具有固定在其中的大体上敞开且中空的流动混合器主体的流动导体; 以及位于大体上敞开的中空流动混合器主体的入口处的主要添加剂流注入器，其中当主体流流过时，主要添加剂流注入器将流动混合器的内部流向流动方向的内部注入流动混合器的内部通常是开放和中空的流动混合器主体，以允许将本体流和添加剂流压缩和扩展在一起，以便于在延伸流动混合器的出口处混合本体流和初级添加剂流，其中遵循该拉伸流动混合器通过至少一个螺旋静态混合元件，其是在延伸流动混合器的出口下游的至少一个半流动导体直径。

15. 发明授权

US08846690B2 Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring 有权
标题翻译：具有2,5-取代的恶唑并嘧啶环的杂环羧酸衍生物
公开(公告)号：US08846690B2
公开(公告)日：2014-09-30
申请号：US13521828
申请日：2011-01-12
申请人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Katrin Hiss
发明人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Katrin Hiss
IPC分类号： A01N43/90 , A61K31/519 , C07D239/00 , C07D498/04
CPC分类号： C07D498/04
摘要： Heterocyclic carboxylic acid derivatives comprising a 2,5-substituted oxazolopyrimidine ring as Edg-1 receptor agonistsThe present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R1, R2, R3, X and Y are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
摘要翻译：包含2,5-取代的恶唑啉嘧啶环作为Edg-1受体激动剂的杂环羧酸衍生物本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1，R 2，R 3，X和Y如声称。式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于例如治疗动脉粥样硬化，心力衰竭或外周动脉闭塞性疾病等疾病。本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。

16. 发明授权

US08785439B2 2,5,7-substituted oxazolopyrimidine derivatives 有权
标题翻译： 2,5,7-取代的恶唑并嘧啶衍生物
公开(公告)号：US08785439B2
公开(公告)日：2014-07-22
申请号：US13521823
申请日：2011-01-12
申请人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Andreas Gille , Katrin Hiss
发明人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Andreas Gille , Katrin Hiss
IPC分类号： C07D401/00 , C07D498/04
CPC分类号： C07D498/04
摘要： The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2 and R3 are defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing.
摘要翻译：本发明涉及式（I）的恶唑并嘧啶化合物，其中A，R 1，R 2和R 3如权利要求中所定义。式（I）化合物适用于例如伤口愈合。

17. 发明授权

US08735387B2 Oxazolopyrimidines as Edg-1 receptor agonists 有权
标题翻译： Oxazolopyrimidines作为Edg-1受体激动剂
公开(公告)号：US08735387B2
公开(公告)日：2014-05-27
申请号：US13003125
申请日：2009-07-02
申请人： Dieter Kadereit , Matthias Schaefer , Werngard Czechtizky
发明人： Dieter Kadereit , Matthias Schaefer , Werngard Czechtizky
IPC分类号： C07D498/04 , A61K31/519 , A61P9/00 , A61P9/10 , A61P29/00 , A61P25/28 , A61P35/00
CPC分类号： C07D498/04 , C07D519/00
摘要： The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
摘要翻译：本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1，R 2和R 3如权利要求中所定义。式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于例如治疗动脉粥样硬化，心力衰竭或外周动脉闭塞性疾病等疾病。本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。

18. 发明申请

US20130137685A1 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES 有权
标题翻译： 2,5,7-取代的氧杂环糊精衍生物
公开(公告)号：US20130137685A1
公开(公告)日：2013-05-30
申请号：US13521823
申请日：2011-01-12
申请人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Andreas Gille , Katrin Hiss
发明人： Dieter Kadereit , Matthias Schaefer , Stephanie Hachtel , Axel Dietrich , Thomas Huebschle , Andreas Gille , Katrin Hiss
IPC分类号： C07D498/04
CPC分类号： C07D498/04
摘要： The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2 and R3 are defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing.
摘要翻译：本发明涉及式（I）的恶唑并嘧啶化合物，其中A，R 1，R 2和R 3如权利要求中所定义。式（I）化合物适用于例如伤口愈合。

19. 发明授权

US08362073B2 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals 有权
标题翻译：酰氨基取代的稠环戊烷羧酸衍生物及其作为药物的用途
公开(公告)号：US08362073B2
公开(公告)日：2013-01-29
申请号：US12939650
申请日：2010-11-04
申请人： Matthias Schaefer , Josef Pernerstorfer , Dieter Kadereit , Hartmut Strobel , Werngard Czechtizky , L. Charlie Chen , Alena Safarova , Aleksandra Weichsel , Marcel Patek
发明人： Matthias Schaefer , Josef Pernerstorfer , Dieter Kadereit , Hartmut Strobel , Werngard Czechtizky , L. Charlie Chen , Alena Safarova , Aleksandra Weichsel , Marcel Patek
IPC分类号： A61K31/166 , C07C231/02
CPC分类号： C07C235/54 , A61K31/196 , A61K31/216 , A61K31/277 , A61K31/381 , A61K31/439 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/495 , A61K31/4965 , C07C231/02 , C07C235/62 , C07C235/84 , C07C237/38 , C07C255/54 , C07C255/57 , C07C255/58 , C07C307/10 , C07C309/73 , C07C311/08 , C07C315/04 , C07C317/22 , C07C317/46 , C07C319/12 , C07C319/20 , C07C321/26 , C07C323/12 , C07C323/19 , C07C323/42 , C07C323/62 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D207/08 , C07D207/09 , C07D207/263 , C07D209/12 , C07D209/44 , C07D211/22 , C07D213/30 , C07D213/65 , C07D213/68 , C07D213/73 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D221/04 , C07D231/12 , C07D233/54 , C07D233/64 , C07D233/84 , C07D235/12 , C07D235/18 , C07D241/38 , C07D249/06 , C07D261/04 , C07D261/20 , C07D263/32 , C07D271/08 , C07D277/24 , C07D277/56 , C07D285/06 , C07D295/08 , C07D295/20 , C07D305/06 , C07D307/12 , C07D309/06 , C07D319/06 , C07D319/12 , C07D319/20 , C07D333/16 , C07D333/38 , C07D333/56 , C07D333/78 , C07D413/04 , C07D417/04 , C07D453/02 , C07D471/08
摘要： The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
摘要翻译：本发明涉及式I化合物，其中A，Y，Z，R 3至R 6，R 20至R 22和R 50具有权利要求中所示的含义，它们是有价值的药物活性化合物。具体来说，它们是由溶血磷脂酸（LPA）激活的内皮分化基因受体2（Edg-2，EDG2）的抑制剂，也被称为LPA1受体，可用于治疗动脉粥样硬化，心肌的疾病梗死和心力衰竭。本发明还涉及制备式I化合物的方法，其用途和包含它们的药物组合物。

20. 发明申请

US20110190490A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS 有权
标题翻译：氧自由基作为EDG-1受体激动剂
公开(公告)号：US20110190490A1
公开(公告)日：2011-08-04
申请号：US13003125
申请日：2009-07-02
申请人： Dieter Kadereit , Matthias Schaefer , Werngard Czechtizky
发明人： Dieter Kadereit , Matthias Schaefer , Werngard Czechtizky
IPC分类号： C07D413/14 , C07D471/04
CPC分类号： C07D498/04 , C07D519/00
摘要： The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
摘要翻译：本发明涉及式I的恶唑并嘧啶化合物，其中A，R 1，R 2和R 3如权利要求中所定义。式I的化合物调节Edg-1受体的活性，特别是该受体的激动剂，并且可用于例如治疗动脉粥样硬化，心力衰竭或外周动脉闭塞性疾病等疾病。本发明还涉及制备式I化合物的方法，其用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式